TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9385475

Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg
Number of subjects: 501

Group type: COMPARATOR
Intervention: Lisinopril 2.5 mg
Number of subjects: 501
Study: 7953037

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention delivered by trained community psychiatric nurses (CPNs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 48
Study: 3617239

Group type: EXPERIMENTAL
Intervention: Combined intramuscular and oral estrogen treatment (ESTR, n = 39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Orchidectomy (ORX, n = 41)
Number of subjects: 80
Study: 28643356

Group type: EXPERIMENTAL
Intervention: Bimagrumab
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27439527

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Nevirapine (NVP)
Number of subjects: 451
Study: 25111732

Group type: EXPERIMENTAL
Intervention: Ownership information taught to children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labeling information taught to children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adults tracking object identity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unrelated dimension (preference)
Number of subjects: 0
Study: 22211444

Group type: EXPERIMENTAL
Intervention: Group therapy intervention to decrease HIV-related risk behavior and trauma-related stress symptoms
Number of subjects: 167
Study: 20585067

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 65229
Study: 18616068

Group type: EXPERIMENTAL
Intervention: Health services research (HSR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiropractic studies
Number of subjects: 0
Study: 15987864

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (20 mg thiamine, 20 mg riboflavin, 25 mg B-6, 50 microg B-12, 500 mg C, 30 mg E, and 0.8 mg folic acid)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (30 mg beta-carotene plus 5000 IU preformed vitamin A)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: High baseline systolic blood pressure (>120 mm Hg)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Higher mid-upper arm circumference
Number of subjects: 1078
Study: 11909925

Group type: EXPERIMENTAL
Intervention: Suggestion techniques during outpatient video EEG recording
Number of subjects: 30

Group type: COMPARATOR
Intervention: No suggestion during outpatient video EEG recording
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with a history of previous events in medical settings
Number of subjects: 30
Study: 10702649

Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reactive hyperemia
Number of subjects: 42
Study: 8709296

Group type: EXPERIMENTAL
Intervention: 5 days of abstinence
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0 days of abstinence
Number of subjects: 12
Study: 1930765

Group type: EXPERIMENTAL
Intervention: narrative story
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: method of loci
Number of subjects: 71

Group type: COMPARATOR
Intervention: placebo training
Number of subjects: 71
Study: 6178915

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30417332

Group type: COMPARATOR
Intervention: Telephone disclosure
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: In-person disclosure
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Pretest counseling
Number of subjects: 1178
Study: 30064474

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (RG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Laparoscopic gastrectomy (LG)
Number of subjects: 240
Study: 27899067

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (25 mg)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Total effect of hydroxyzine
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Conventionally estimated drug effect
Number of subjects: 480
Study: 25298576

Group type: EXPERIMENTAL
Intervention: Conventional interferon (INF) α2a, 3MIU, S.C and ribavirin 1000 mg PO for 24 weeks in genotype 3 and 48 weeks in genotype 1 and 4 HCV patients.
Number of subjects: 60
Study: 22670901

Group type: EXPERIMENTAL
Intervention: Delamanid 100 mg twice daily
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Delamanid 200 mg twice daily
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 23120682

Group type: EXPERIMENTAL
Intervention: Cefazolin prophylaxis for 2 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cefazolin prophylaxis for 5 days
Number of subjects: 90
Study: 17885344

Group type: EXPERIMENTAL
Intervention: Heatwrap therapy in addition to oral analgesics
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral analgesics (control group)
Number of subjects: 30
Study: 16304476

Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: WB-MRI
Number of subjects: 41
Study: 12183263

Group type: EXPERIMENTAL
Intervention: Gentamicin concentration at surgical closure < 0.5 mg/liter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gentamicin concentration at surgical closure ≥ 1.6 mg/liter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Presence of diabetes mellitus
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Presence of stoma
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 10
Study: 10728175

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for bulimia nervosa
Number of subjects: 94
Study: 9815934

Group type: EXPERIMENTAL
Intervention: Cisplatin, 80 mg/m2, three times every 3 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Carboplatin, 375 mg/m2, three times every 3 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation therapy
Number of subjects: 73
Study: 1952429

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.025 mg/kg body weight)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 7
Study: 7281826

Group type: EXPERIMENTAL
Intervention: 20 mg PETN
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 40 mg PETN
Number of subjects: 17
Study: 30698277

Group type: EXPERIMENTAL
Intervention: In-group targets
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Syrian targets
Number of subjects: 214

Group type: COMPARATOR
Intervention: General reasoning about three groups
Number of subjects: 214
Study: 30765429

Group type: EXPERIMENTAL
Intervention: Proximal glucose infusion (30 g glucose with 3 g 3-O-methylglucose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Distal glucose infusion (30 g glucose with 3 g 3-O-methylglucose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous isoglycemic clamp studies
Number of subjects: 20
Study: 28993935

Group type: EXPERIMENTAL
Intervention: Surgical treatment (n=39)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-surgical treatment (n=18)
Number of subjects: 57
Study: 25350916

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 0
Study: 23828481

Group type: EXPERIMENTAL
Intervention: Endobronchial valve therapy (EBV)
Number of subjects: 169
Study: 22089651

Group type: EXPERIMENTAL
Intervention: HFSC program (usual care plus HFSC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27
Study: 19651956

Group type: EXPERIMENTAL
Intervention: Cemented all-polyethylene keeled glenoid component
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cemented all-polyethylene in-line three-pegged glenoid component
Number of subjects: 25
Study: 17581811

Group type: EXPERIMENTAL
Intervention: Web-based program
Number of subjects: 419

Group type: COMPARATOR
Intervention: Print materials
Number of subjects: 419
Study: 15084552

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 100
Study: 15941455

Group type: EXPERIMENTAL
Intervention: Day treatment programme (n = 21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Traditional outpatient programme (n = 22)
Number of subjects: 43
Study: 14528540

Group type: COMPARATOR
Intervention: Provider prompting intervention alone
Number of subjects: 1318

Group type: COMPARATOR
Intervention: Provider prompting and tailored print materials
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Provider prompting, tailored print communications and tailored telephone counseling
Number of subjects: 1318
Study: 8552798

Group type: EXPERIMENTAL
Intervention: Marketing strategy to promote research-based nursing care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (standard nursing care)
Number of subjects: 20
Study: 1862125

Group type: EXPERIMENTAL
Intervention: PDWHF (purified platelet releasate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 6600426

Group type: EXPERIMENTAL
Intervention: Aspirin (2.6 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31447226

Group type: EXPERIMENTAL
Intervention: Carbohydrate diet (CARB)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Protein diet (PROT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Unsaturated fat diet (UNSAT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: All diets (CARB, PROT, UNSAT)
Number of subjects: 164
Study: 30578873

Group type: EXPERIMENTAL
Intervention: Risankizumab (90 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Risankizumab (180 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 81

Group type: COMPARATOR
Intervention: Risankizumab and Ustekinumab
Number of subjects: 81
Study: 28860170

Group type: EXPERIMENTAL
Intervention: Sodium carbonate‐bicarbonate buffer (SCB‐HCl; pH 7.4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.02% ethanol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2% dimethyl sulfoxide (DMSO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (lactated Ringer's)
Number of subjects: 8
Study: 27298211

Group type: EXPERIMENTAL
Intervention: Online community intervention (n=99)
Number of subjects: 216

Group type: COMPARATOR
Intervention: No online community (diary) condition (n=117)
Number of subjects: 216
Study: 25927187

Group type: EXPERIMENTAL
Intervention: Training and support to deliver Positive Behaviour Support (PBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 23326011

Group type: EXPERIMENTAL
Intervention: Functional endoscopic dilatation sinus surgery (FEDS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 24
Study: 19776683

Group type: EXPERIMENTAL
Intervention: High group (target serum glucose concentration 9‐11 mmol/l)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low group (target serum glucose concentration 5‐7 mmol/l)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low group
Number of subjects: 68
Study: 17276272

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with intracameral nonpreserved lidocaine 0.5% (Group 2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Topical anesthesia with 0.15 mL intracameral placebo (Group 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 33
Study: 15047656

Group type: EXPERIMENTAL
Intervention: HbA(1c) <8.4% (low HbA(1c) group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: HbA(1c) > or = 8.4% (high HbA(1c) group)
Number of subjects: 39
Study: 12202468

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (placebo or calcium/vitamin D)
Number of subjects: 57
Study: 9825370

Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg over 15 minutes followed by 10 mg/kg over the next 24 hours)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg intravenously over 1 hour, followed by 20 mg/kg over the next 24 hours, plus 1,800 mg/day orally, in 3 divided doses)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo (equivalent amount of saline i.v. over 24 hours)
Number of subjects: 143
Study: 7926530

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen inhalation (n = 30)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional intravenous sedation (pethidine 50 mg, midazolam 2.5 mg) (n = 29)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 89
Study: 30010481

Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 372

Group type: COMPARATOR
Intervention: US-RTX
Number of subjects: 372

Group type: COMPARATOR
Intervention: EU-RTX
Number of subjects: 372

Group type: COMPARATOR
Intervention: CT-P10 vs RTX
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: CT-P10 and RTX
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: CT-P10, US-RTX, and EU-RTX
Number of subjects: 372
Study: 27797437

Group type: EXPERIMENTAL
Intervention: Standard and intense blood pressure goals (<120/80 mm Hg)
Number of subjects: 149
Study: 24713048

Group type: EXPERIMENTAL
Intervention: TiZr implants
Number of subjects: 91

Group type: COMPARATOR
Intervention: Ti Grade IV implants
Number of subjects: 91
Study: 24006085

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) in combination with chemotherapy
Number of subjects: 46
Study: 20868428

Group type: EXPERIMENTAL
Intervention: G1 - Sensodyne® (n=52)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: G2 - SensiKill® (n=62)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: G3 - Biosilicate® incorporated in a 1% water‐free‐gel (n=59)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: G4 - Biosilicate® mixed with distilled water at 1:10 ratio (n=59)
Number of subjects: 120
Study: 19066100

Group type: EXPERIMENTAL
Intervention: Surgical treatment (within 7-24 hours)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgical treatment (ultra-early stage < or = 7 h)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgical treatment (delayed stage > 24 h)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 500
Study: 16860796

Group type: EXPERIMENTAL
Intervention: Women with unexplained recurrent miscarriage
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy fertile women
Number of subjects: 37
Study: 12593901

Group type: EXPERIMENTAL
Intervention: Coil removal prior to treatment
Number of subjects: 126

Group type: COMPARATOR
Intervention: No coil removal (Control)
Number of subjects: 126
Study: 11131487

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cisplatin-based)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 19
Study: 9069056

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-frequency positive pressure ventilation (Control)
Number of subjects: 11
Study: 8350219

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (4.4 mg/L; final content, 11 mg/L)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (final content, 6.7 mg/L)
Number of subjects: 52
Study: 3521277

Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg twice daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Naproxen and Placebo
Number of subjects: 11
Study: 30015064

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily + P2Y12 inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily + P2Y12 inhibitor + aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily + P2Y12 inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily + P2Y12 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: VKA-based triple therapy
Number of subjects: 0
Study: 27177859

Group type: EXPERIMENTAL
Intervention: Patients' use of acceptance coping
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Patients' use of emotional support coping
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Patients reporting primary goal of treatment as 'cure my cancer'
Number of subjects: 275

Group type: COMPARATOR
Intervention: FCs reporting depression
Number of subjects: 275

Group type: COMPARATOR
Intervention: Patients reporting depression
Number of subjects: 275

Group type: COMPARATOR
Intervention: FCs reporting anxiety
Number of subjects: 275

Group type: COMPARATOR
Intervention: Patients reporting anxiety
Number of subjects: 275
Study: 23885105

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Elagolix 250 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Elagolix (both dosages)
Number of subjects: 155
Study: 22919982

Group type: EXPERIMENTAL
Intervention: Blue-light phototherapy using the Siriraj Phototherapy Lamp with 6 special blue fluorescent tubes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Light-emitting diodes (LEDs) phototherapy using the Bilitron 3006 with 5 super LEDs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blue-light phototherapy
Number of subjects: 40
Study: 19696753

Group type: EXPERIMENTAL
Intervention: Modest energy deficit diet for 8 weeks (study A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low energy liquid diet for 6 weeks (study B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QMR measurement
Number of subjects: 0
Study: 18383972

Group type: EXPERIMENTAL
Intervention: Higher oxygen concentration
Number of subjects: 1661
Study: 16280742

Group type: EXPERIMENTAL
Intervention: ALA assisted TUR
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard white light TUR
Number of subjects: 115
Study: 12090980

Group type: EXPERIMENTAL
Intervention: Intranasal 4% sodium cromoglicate spray
Number of subjects: 290

Group type: COMPARATOR
Intervention: Intranasal normal saline spray
Number of subjects: 290
Study: 10369155

Group type: EXPERIMENTAL
Intervention: Marital partner death
Number of subjects: 2

Group type: COMPARATOR
Intervention: Marital partner myocardial infarction
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Previous psychiatric consultation history
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Limited individual coping skills
Number of subjects: 2
Study: 8619016

Group type: COMPARATOR
Intervention: Melatonin (0.5 mg) for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2045293

Group type: COMPARATOR
Intervention: 67.2 Gy
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: 72.0 Gy
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: 76.8 Gy
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: 81.6 Gy
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Interfraction interval ≤ 4.5 hours
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Interfraction interval > 4.5 hours
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 447
Study: 6119168

Group type: EXPERIMENTAL
Intervention: Oxatomide (2 mg/kg by mouth)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate powder (20 mg by inhalation)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matched placebo preparations
Number of subjects: 8
Study: 31129603

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes with nicotine (ECwN) plus placebo tablets of varenicline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electronic cigarettes without nicotine (ECwoN) plus placebo tablets of varenicline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes without nicotine (ECwoN) plus 0.5 mg varenicline tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 0
Study: 30235712

Group type: EXPERIMENTAL
Intervention: 5, 10, 15, 20, and 25 μg epidural sufentanil as an adjuvant with 10 mL of 0.65% ropivacaine
Number of subjects: 100
Study: 26921890

Group type: EXPERIMENTAL
Intervention: Medication-specific education (video and written information about the medication prescribed)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no medication-specific education)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medication-specific education
Number of subjects: 100
Study: 24508294

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation for 3 months
Number of subjects: 59
Study: 22180217

Group type: EXPERIMENTAL
Intervention: Locally-delivered doxycycline microspheres with scaling and root planing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Locally-delivered doxycycline microspheres
Number of subjects: 20
Study: 20675354

Group type: EXPERIMENTAL
Intervention: School-based natural mentoring relationships
Number of subjects: 3320
Study: 17539693

Group type: EXPERIMENTAL
Intervention: Antipsychotic drug regimens that do not adversely affect major risk factors for CVD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study: 16111947

Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 209
Study: 12115219

Group type: EXPERIMENTAL
Intervention: Triple combination of methotrexate (MTX), hydroxychloroquine (HCQ), and sulfasalazine (SSZ)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and hydroxychloroquine (HCQ)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and sulfasalazine (SSZ)
Number of subjects: 171
Study: 10195337

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with neuroleptics
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unmedicated schizophrenic patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30